PR Newswire
MELBOURNE, Australia , Feb. 11, 2021 /PRNewswire/ -- Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that is has signed a Research Agreement with MSD , the tradename of Merck & Co., Inc ., Kenilworth NJ USA. Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma's proprietary DEP ® technology.
Dr Jackie Fairley , CEO of Starpharma commented: "MSD is a recognised leader in oncology, and we are delighted to have signed this new Research Agreement in such an innovative and valuable area."
DEP ® ADCs exploit the unique potential of Starpharma's DEP ® technology to provide enhanced characteristics to ADCs including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventional ADC approaches. DEP ® ADCs are the subject of internal and partnered programs.
Starpharma has previously demonstrated the significant advantages conveyed by DEP ® ADCs in multiple preclinical studies, including its DEP ® HER-2 ADC, which showed significant tumour regression and 100% survival, outperforming Herceptin & Kadcyla in a human ovarian cancer model. Starpharma's DEP ® technology has already yielded four clinical stage oncology products, including one under development by AstraZeneca.
Media: Sumit Media Grant Titmus Mob: +61 419 388 161 | Starpharma Holdings Limited Dr Jackie Fairley, Chief Executive Officer Nigel Baade, CFO and Company Secretary investor.relations@starpharma.com 4-6 Southampton Crescent Abbotsford Vic 3067 | Disclosure
|
SOURCE Starpharma